- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
A study published this week in the US Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report (MMWR) provided further evidence of the benefits of vaccination. The study examined the benefits of a third dose of mRNA vaccine (Pfizer/BioNTech or Moderna) on preventing hospitalisation for COVID-19. Nearly 3,000 adults in 18 states were included in the study, about half were positive for COVID-19, and half were negative. The data were evaluated for the time period from late-August through 15 December 2021 when the Delta variant was dominating the globe. The results showed vaccine efficacy was improved against COVID-19-associated hospitalisation after receiving the third dose. Ultimately, in adults without immunocompromise, vaccine effectiveness against hospitalisation was 82% for two doses, and 97% for three.
Further information on vaccines may be found here.
Further information on variants may be found here.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
